Ovarian Cancer Breakthrough Heralds New Era of Treatment - Advice From Doctor - TCM network 
简体版
繁体版
English
 
Main Page
Diseases Encyclopedia
TCM-News
Advice From Doctor
Diet Therapy
TCM-Health Wellness
Sexual Health
Health Column
Special-featured therapy
Chinese Herbs
TCM-Acupunture
TCM-Tuina
Gufang message
Contact Us
 

China TCM web

Patients should try to come to consult us personally, for those that cannot do that, please send or fax to the professional group your recent symptoms, examination, analysis, early diagnose and case history (including patient's address, telephone number, height, weight), after discussion and diagnosis by the professional group, the treatment plan will be informed to the patient and he/she should receive treatment by postage. One can consult the professional group anytime during the treatment.
 

Contact Us
Tel: +0086 13631453379
Contact:Miss Wang
Email:yizi-ice@hotmail.com
Address:Bei Xi Liu Lu Zhan Dian Zi Bo Shan Dong China
Remittance/Payment:

>>> TCM network - Advice From Doctor  
Doctor Profile
    Dr. Wang Yong, character Shurun,
of Han Nationality, is born to the
Chinese  medicine  aristocratic
family,he has inherited the essence
of traditional Chinese medicine,he
uses ancient secret remedies as the
base and he complies........more
 
Gufang Introduction
    Gufang Chinese medicine
complicated diseases research center
is located at Shan Dong Province Zi
Bo City , ZhangDian Bei Xi Liu Road;
Zi Bo is situated between Lu Zhong
mountain area andLuBei champagne,
located at a unique......more
 
Ovarian Cancer Breakthrough Heralds New Era of Treatment
2009-06-12 【font size: Large Medium Small】  【Close
----------------------------------------------------------------------------------------------------------------------------------------

  Canadian researchers have zeroed in on the cause of a deadly type of ovarian cancer, a finding that could lead to successful treatment of the rare granulosa cell tumors.


  The culprit is a single mutation out of 3 billion nucleotide pairs that make up the genetic code of the tumor. The mutation is present in every granulosa cell tumor, a rare and often untreatable form of ovarian cancer that affects about 5 percent of ovarian cancer patients, according to a study that appears in the June 10 online issue of the New England Journal of Medicine.


  The discovery, made using state-of-the-art gene-sequencing technologies, may mark the beginning of a new era of cancer genomics, in which the complete genetic sequence of cancers and the mutations that cause them can be identified, researchers said.


  For women with granulosa cell tumors, the precise identification of the mutation may help in developing new, badly needed treatments.


  'This is really a two-fold discovery,' said lead study author Dr. David Hunstman, a genetic pathologist at the BC Cancer Agency and Vancouver General Hospital and an associate professor at the University of British Columbia.


  'It clearly shows the power of the new generation of DNA sequencing technologies to impact clinical medicine, and for those of us in the area of ovarian cancer research and care, by identifying the singular mutation that causes granulosa cell tumors, we can now more easily identify them and develop new ways to treat them,' he added in a university news release.


  In the study, researchers decoded four granulosa cell tumors using 'next generation' sequencing machines that decode billions of nucleotides at rapid speed and new computer techniques to quickly assemble the data.


  While most types of cancer, including ovarian cancers, have a broad range of genetic abnormalities, researchers found a mutation in a single nucleotide in the FOXL2 gene in every sample.


  The research team further validated the findings by examining additional tumor samples from across Canada and around the world.


  In the past, analyzing the sequence of a tumor was a laborious process, and most studies could only look at one or only a few of the 20,000 genes in the human genome. The new sequencing technologies allow scientists to look at all at once.


  'This task would have been unfathomable in terms of both cost and complexity even two years ago,' said Dr. Marco Marra, director of the BC Cancer Agency's Genome Sciences Center.


  Researchers chose granulosa cell tumors because, unlike other cancers, they are 'clinically homogenous,' Huntsman said.


  'This cancer is unique,' said Dr. Dianne Miller, a gynecologic oncologist at BC Cancer Agency and Vancouver General Hospital. 'For patients with this tumor type, it means they should all have the same response to the same treatment. And now that we have this pathway, we can look for existing cancer drugs that might work on this particular gene mutation to make the cancer disappear.'

 


 

guanliyuan
© 2017 TCM network All rights reserved
RecordNumber:(ICP): LuICPBei05008738